Evidence map›Paper›PMID 28027442›Full record

ArticleACS nano2017

Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.

Liangzhu Feng, Liang Cheng, Ziliang Dong, Danlei Tao, Todd E Barnhart, Weibo Cai, Meiwan Chen, Zhuang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
27.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 433 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Harnessing nanotechnology for cancer treatment.Frontiers in bioengineering and biotechnology · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Liangzhu FengInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University , Suzhou 215123, China.
Liang ChengInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University , Suzhou 215123, China.
Ziliang DongInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University , Suzhou 215123, China.
Danlei TaoInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University , Suzhou 215123, China.
Todd E BarnhartDepartments of Radiology and Medical Physics, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Meiwan ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau , Macau 999078, China.
Zhuang LiuInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University , Suzhou 215123, China.ORCID 0000-0002-1629-1039
Soochow University · CNUniversity of Wisconsin–Madison · USUniversity of Macau · MO

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Novel Combination Therapy for Prostate CancerR01CA169365 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAI, WEIBO · 2013 to 2015
$903k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA169365
6 · The paper itself

Abstract

Photodynamic therapy (PDT), a noninvasive cancer therapeutic method triggered by light, would lead to severe tumor hypoxia after treatment. Utilizing a hypoxia-activated prodrug, AQ4N, which only shows toxicity to cancer cells under hypoxic environment, herein, a multipurpose liposome is prepared by encapsulating hydrophilic AQ4N and hydrophobic hexadecylamine conjugated chlorin e6 (hCe6), a photosensitizer, into its aqueous cavity and hydrophobic bilayer, respectively. After chelating a

Indexed as

PhotochemotherapyTheranostic NanomedicineAminesAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationDose-Response Relationship, DrugFemaleHydrocarbonsHypoxiaLiposomesMicePhotosensitizing AgentsPositron-Emission TomographyAminesAntineoplastic AgentshexadecylamineHydrocarbonsLiposomesPhotosensitizing AgentsProdrugshypoxia-activated therapyliposomesmultimodal imagingphotodynamic therapytumor hypoxia

Identifiers

PMID28027442
PMCPMC5372701
OpenAlexW2567120106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.